Arcturus Therapeutics (NASDAQ:ARCT) executives highlighted progress in two rare-disease clinical programs and outlined a strengthened cash runway during the company’s first-quarter 2026 earnings call,...
Arcturus Therapeutics: Q1 Earnings Snapshot
Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Wood trimmed stakes in Nvidia, Meta, and Tesla; instead, she added this speculative biotech play.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Arcturus Therapeutics: Q4 Earnings Snapshot
ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...
The high price estimate for Arcturus suggests the stock can rally as high as 963%. Is it a far-fetched target?